CARBOHYDRATE METABOLISM DISTURBANCES: THERAPEUTIC POTENTIAL IN METABOLIC SYNDROME

• Main Authors: I. V. Kryuchkova, A. S. Adamchik
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2009-04-01
• Series: Российский кардиологический журнал
• Subjects: metabolic syndrome; chronic heart failure; carbohydrate metabolism; insulin resistance; dibicor
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/1336

The study was focused on dibicor effects on carbohydrate metabolism (CM) and insulin resistance (IR) in patients with metabolic syndrome (MS), as well as the correlations between various CM parameters, chronic heart failure (CHF), and abdominal obesity (AO). In total, 61 patients aged 31–66 years gave their informed consent to participate in the study, including 21,7% of men and 78,3% of women. The control group (n=30) received standard therapy only, while the main group (n=30) also received dibicor. All participants underwent anthropometry, blood pressure and IR measurement, lipid and carbohydrate metabolism assessment. Twelve-month dibicor therapy was associated with improved CM and reduced IR. Functional class (FC) of CHF directly correlated with CM disturbance severity, while AO correlated with fasting and glucose tolerance test levels of plasma glucose. In MS and CHF, dibicor improved CM, reduced IR, and therefore, facilitated the CHF FC reduction.